Back to discover
Disease

Wolff-Parkinson's-White syndrome

Also known as WPW, Wolff-Parkinson-White pattern, Wolff-Parkinson-White pattern (finding), Wolff-Parkinson-white syndrome (disease)+6 more

WPW, Wolff-Parkinson-White pattern, Wolff-Parkinson-White pattern (finding), Wolff-Parkinson-white syndrome (disease), anomalous A-V excitation, anomalous atrioventricular excitation, ventricular familial preexcitation syndrome, Wpw syndrome, accessory atrioventricular pathways, preexcitation syndrome.

12
Associated genes

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Pramipexoleapproved

Approval — Pramipexole Teva is indicated for treatment of the signs and symptoms of idiopathic Parki… (2008)

Rotigotineapproved

Approval — Parkinson's disease: Neupro is indicated for the treatment of the signs and symptoms of e… (2006)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2008emaApproval — Pramipexole· Pramipexole Teva is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations). Pramipexole Teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2). source ↗
2008emaApproval — Pramipexole· Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations). Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2). source ↗
2006emaApproval — Rotigotine· Parkinson's disease: Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations). Restless-legs syndrome: Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults. source ↗
1998emaApproval — Pramipexole· Mirapexin is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations). Mirapexin is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt). source ↗
1997emaApproval — Pramipexole· Sifrol is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, though to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations). Sifrol is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

PRKAG20.74MCUR10.34CASQ20.26RHBDF10.19CYP51A10.14TTC39A0.14GPD1L0.11WWP10.11ERI20.07GATD30.07MVB12A0.07SPATA450.07

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.

Synonyms

WPW, Wolff-Parkinson-White pattern, Wolff-Parkinson-White pattern (finding), Wolff-Parkinson-white syndrome (disease), anomalous A-V excitation, anomalous atrioventricular excitation, ventricular familial preexcitation syndrome, Wpw syndrome, accessory atrioventricular pathways, preexcitation syndrome

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.